Jeanne Whalen at the Wall Street Journal examines the restructuring of R&D at GlaxoSmithKline, and other big drug companies, over the past decade. GSK "has carved its research group into dozens of such small units" in an effort to "turn a sluggish, bureaucratic R&D staff into a constellation of specialized teams capable of discovering cutting-edge drugs — much in the way biotech companies do,"she writes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.